Abstract:

BACKGROUND: Living donor liver transplantation expands the source of donor, relieves the situation of donor liver shortage, and its cold ischemia time is short and quality is good. If the donor and recipient are relatives, it maybe have the merit of immunity interconsistency.
OBJECTIVE: To summarize the clinical experiences of living donor liver transplantation (LDLT) between adult relatives, to explore the operation mode and transplantation effects of living donor liver transplantation between adult relatives for the treatment of end-stage liver disease.
METHODS: The recipient was a 54-year-old woman who had been diagnosing post-hepatitis B cirrhosis (decompensation stage) combine portal hypertension. The donor was the patient’s nephew, who was a 23-year-old man. After surgery evaluation, procurement right lobe and transplantation to recipient, the operation was orthotopic liver transplantation. After the surgery, patient was given immunosuppression prevention of infection, hepatic protection, and other relevant supports, etc.
RESULTS AND CONCLUSION: After surgery the donor had stable life signs, the operative duration for liver procurement was 4 hours, blood loss was about 150 mL, and liver function recovered to normal in 5 days postoperatively. Then he was performed upper abdominal CT scans and enhanced scans that suggested the liver coincided the changes which had been taken the right lobe in living donor transplantation. The recipient’s life sign was stationary, the surgery for live transplantation lasted 7 hours, and blood loss was about 500 mL. Color ultrasonic scan showed that liver vessels were patency, blood supply was satisfactory, and biochemical indexes recovered to normal gradually, which meant the transplantation liver function well. They survived without various complications, the follow-up survey that the function of liver retained normal in outpatient department. The case suggested that adult-to-adult living donor liver transplantation (A-A LDLT) was an excellent way to help tackle the problem of cadaveric liver shortage for treating end-stage liver disease.